Edesa Biotech welcomes Peter J. Weiler as the new Chief Financial Officer, succeeding Stephen Lemieux, effective May 1, 2025. Stephen Lemieux transitions to senior financial advisor, ensuring a smooth leadership…
Edesa Biotech navigates a strategic leadership change with Peter J. Weiler appointed as the new CFO, following Stephen Lemieux's departure. The company focuses on developing treatments for immuno-inflammatory diseases, with…
Suspicious activity alerts can disrupt online experiences, highlighting the need for vigilant digital security. Safeguarding your online identity in today's connected world is essential to maintaining digital presence and trust.…
Online security systems may lock accounts due to unusual activity patterns, such as excessive page views or the use of automation tools. Automated defenses can mistakenly capture benign users, causing…
Peter J. Weiler appointed as new CFO of Edesa Biotech, starting May 1, 2025. Weiler brings extensive experience, with previous roles at Exzell Pharma and Biosyent Inc. Weiler holds an…
Edesa Biotech announces the appointment of Peter J. Weiler as the new Chief Financial Officer (CFO) starting May 2025, succeeding Stephen Lemieux. Peter J. Weiler brings extensive experience from roles…
The appointment of Peter J. Weiler as CFO marks a strategic shift for Edesa Biotech, effective May 1, 2025. Weiler brings extensive experience from roles at Exzell Pharma, Biosyent Inc.,…
March was a challenging month for early-stage biotech stocks, with notable companies like Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics experiencing significant share price declines. Biohaven's drug candidate BHV-7000 underperformed in…
Biotechnology innovation drives new therapies, with small and mid-size pharma firms playing a key role despite the challenges posed by larger companies and complex regulations. The global biotechnology market is…
Viva Biotech Holdings has experienced a remarkable 29% stock price increase over the past month, and a staggering 231% rise over the past year. The company boasts an attractive low…